A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants

Inclusion Criteria: * 1\. Capable of understanding the written informed consent document; willingly provides valid, signed written informed consent; * 2\. Males and females aged 18 to 65 years old (inclusive) at the time of signing the ICF. * 3.No history of past or current diseases or abnormalities involving the cardiac, hepatic, renal, gastrointestinal, nervous, respiratory, or ocular systems, as well as psychiatric or metabolic abnormalities, that are clinically significant as judged by the investigator. * 4.Participants must be confirmed healthy through medical history, VS, physical examination, clinical laboratory tests , and a 12-lead ECG; * 5\. Body mass index (BMI) of 18.0 to 32.0 kg/m2 inclusive and body weight not less than 50 kg at the time of screening and Day -1. * 6\. Participants must agree to take the investigator-approved effective contraceptive measures during the trial as required by the investigator. * 7.Normal renal function (defined as eGFR ≥ 80 mL/min/1.73 m2) at screening and Day -1. * 8\. Ability to swallow and retain oral medication. * 9.No suicidal ideation, as demonstrated by a score of "0" on the Columbia Suicide Severity Rating Scale (C-SSRS) at screening or Day -1. Exclusion Criteria: * 1.Known hypersensitivity to LWP779 or any of its constituents. * 2.Known or suspected tumor. * 3.History of unexplained syncope, symptomatic hypotension or hypoglycemia. * 4.Presence of orthostatic hypotension at screening or Day -1. * 5.Participants with any …